We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: Apellis Pharmaceuticals, Inc. is a clinical-stage biotech focused on the development of novel therapeutics, which work through the inhibition of the complement system, specially targeting the C3 protein of the complement system to treat autoimmune and inflammatory diseases.
- Recent APLS Stock Price: $42.30
- Yearly Gain for APLS stock: -53.71%
- Market Cap for APLS stock: $5.13B
- P/E Ratio for APLS stock: -9.51
Will APLS's stock price go up? Is there an accurate APLS stock forecast available?
TipRanks.com reports that Apellis Pharmaceuticals, Inc. currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $74.80. The target pricing ranges from a high APLS forecast of $92 down to a low forecast of $57. Apellis Pharmaceuticals, Inc. (APLS)’s last closing stock price was $42.30 which would put the average price target at 76.83% upside.
In addition, TradingView issued a rating for APLS stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has short-term outlook. Remember, securities are volatile, so please do your own research on APLS stock.
Other analysts covering APLS include:
- Douglas Tsao of H.C. Wainwright issued a Buy rating with the price target of $92 on 18 hours ago
- Yigal Nochomovitz of Citi issued a Buy rating with the price target of $60 on 1 day ago
- Akash Tewari of Jefferies issued a Buy rating with the price target of $80 on 1 day ago
- Joseph Stringer of Needham issued a Buy rating with the price target of $85 on 1 day ago
If you are wondering if APLS is a good stock to buy, here are 3rd party ratings for APLS stock:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Top 36% (90 out of 251)
What is the sentiment on the street regarding Apellis Pharmaceuticals, Inc.? (Current ratings compiled by TipRanks.com)
- News Sentiment for APLS stock: Bearish
- Blogger Consensus for APLS stock:
- Media Buzz for APLS stock: Sell
- Insider Signal for APLS stock: Balanced
- Investor Sentiment for APLS stock: Positive
- Hedge Fund signal for APLS stock: High Risk
The stock market is extremely volatile, and you need to do your own research on APLS stock including scouring the social networks like APLS StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for APLS stock chart >>
Summary: Surgery Partners, Inc. is a healthcare services company. The Company's outpatient delivery model focused on providing solutions for surgical and related ancillary care in support of its patients and physicians. Its operating segment consists of Surgical Facility Services segment, Ancillary Services segment and Optical Services segment. Surgery Partners, Inc. is based in Nashville, Tennessee.
- Recent SGRY Stock Price: $27.17
- Yearly Gain for SGRY stock: -22.53%
- Market Cap for SGRY stock: $3.45B
- P/E Ratio for SGRY stock: 2717
Will SGRY's stock price go up? Is there an accurate SGRY stock forecast available?
TipRanks.com reports that Surgery Partners, Inc. currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $43.00. The target pricing ranges from a high SGRY forecast of $50 down to a low forecast of $35. Surgery Partners, Inc. (SGRY)’s last closing stock price was $27.17 which would put the average price target at 58.26% upside.
In addition, TradingView issued a rating for SGRY stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has short-term outlook. Remember, securities are volatile, so please do your own research on SGRY stock.
Other analysts covering SGRY include:
- Andrew Mok CFA of Barclays issued a Hold rating with the price target of $35 on 18 hours ago
- Bill Sutherland of Benchmark Co. issued a Buy rating with the price target of $50 on 18 hours ago
- Ben Hendrix of RBC Capital issued a Buy rating with the price target of $49 on 1 day ago
- Kevin Fischbeck of Bank of America Securities issued a Buy rating with the price target of $40 on 1 day ago
If you are wondering if SGRY is a good stock to buy, here are 3rd party ratings for SGRY stock:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Top 35% (87 out of 251)
What is the sentiment on the street regarding Surgery Partners, Inc.? (Current ratings compiled by TipRanks.com)
- News Sentiment for SGRY stock: Bullish
- Blogger Consensus for SGRY stock:
- Media Buzz for SGRY stock: Neutral
- Insider Signal for SGRY stock: Selling
- Investor Sentiment for SGRY stock: Negative
- Hedge Fund signal for SGRY stock: High Risk
The stock market is extremely volatile, and you need to do your own research on SGRY stock including scouring the social networks like SGRY StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for SGRY stock chart >>
Summary: Alphatec Holdings, Inc. is a medical technology company focused on the design, development, manufacturing and marketing of products for the surgical treatment of spine disorders. The Company's principal product offering includes a variety of spinal implant products and systems consisted of components, such as spine screws and rods, spinal spacers, plates, and various biologics offerings. Alphatec Holdings, Inc. is headquartered in Carlsbad, California.
- Recent ATEC Stock Price: $10.60
- Yearly Gain for ATEC stock: -28.62%
- Market Cap for ATEC stock: $1.48B
- P/E Ratio for ATEC stock: -6.88
Will ATEC's stock price go up? Is there an accurate ATEC stock forecast available?
TipRanks.com reports that Alphatec Holdings, Inc. currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $23.60. The target pricing ranges from a high ATEC forecast of $32 down to a low forecast of $17. Alphatec Holdings, Inc. (ATEC)’s last closing stock price was $10.60 which would put the average price target at 122.64% upside.
In addition, TradingView issued a rating for ATEC stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has short-term outlook. Remember, securities are volatile, so please do your own research on ATEC stock.
Other analysts covering ATEC include:
- David Saxon of Needham issued a Buy rating with the price target of $23 on 18 hours ago
- Brooks O'Neil of Lake Street issued a Buy rating with the price target of $32 on 18 hours ago
- Vik Chopra of Wells Fargo issued a Buy rating with the price target of $26 on 18 hours ago
- Sean Lee CFA of H.C. Wainwright issued a Buy rating with the price target of $20 on 18 hours ago
If you are wondering if ATEC is a good stock to buy, here are 3rd party ratings for ATEC stock:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Top 39% (99 out of 251)
What is the sentiment on the street regarding Alphatec Holdings, Inc.? (Current ratings compiled by TipRanks.com)
- News Sentiment for ATEC stock: Bearish
- Blogger Consensus for ATEC stock:
- Media Buzz for ATEC stock: Neutral
- Insider Signal for ATEC stock: Selling
- Investor Sentiment for ATEC stock: Negative
- Hedge Fund signal for ATEC stock: High Risk
The stock market is extremely volatile, and you need to do your own research on ATEC stock including scouring the social networks like ATEC StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for ATEC stock chart >>
Summary: Rocket Pharmaceuticals, Inc. is an emerging, clinical-stage biotechnology company. It focused on developing first-in-class gene therapy treatment options for rare, undertreated diseases. Rocket Pharmaceuticals Inc., formerly known as Inotek Pharmaceuticals Corporation, is based in LEXINGTON, United States.
- Recent RCKT Stock Price: $22.98
- Yearly Gain for RCKT stock: 7.58%
- Market Cap for RCKT stock: $2.09B
- P/E Ratio for RCKT stock: -8.06
Will RCKT's stock price go up? Is there an accurate RCKT stock forecast available?
TipRanks.com reports that Rocket Pharmaceuticals, Inc. currently has 4 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $50.75. The target pricing ranges from a high RCKT forecast of $53 down to a low forecast of $48. Rocket Pharmaceuticals, Inc. (RCKT)’s last closing stock price was $22.98 which would put the average price target at 120.84% upside.
In addition, TradingView issued a rating for RCKT stock over the next month, Barchart.com has a sell rating and Yahoo! Finance has short-term outlook. Remember, securities are volatile, so please do your own research on RCKT stock.
Other analysts covering RCKT include:
- Gil Blum of Needham issued a Buy rating with the price target of $53 on 1 day ago
- Dae Gon Ha of Stifel Nicolaus issued a Buy rating with the price target of $48 on 1 day ago
- Whitney Ijem of Canaccord Genuity issued a Buy rating with the price target of $49 on 2 days ago
If you are wondering if RCKT is a good stock to buy, here are 3rd party ratings for RCKT stock:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Short-Term Outlook
- Barchart.com: sell
- Zacks.com: Hold, Top 36% (90 out of 251)
What is the sentiment on the street regarding Rocket Pharmaceuticals, Inc.? (Current ratings compiled by TipRanks.com)
- News Sentiment for RCKT stock: Bullish
- Blogger Consensus for RCKT stock:
- Media Buzz for RCKT stock: Sell
- Insider Signal for RCKT stock: Selling
- Investor Sentiment for RCKT stock: Positive
- Hedge Fund signal for RCKT stock: High Risk
The stock market is extremely volatile, and you need to do your own research on RCKT stock including scouring the social networks like RCKT StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for RCKT stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================